Rating Change: STRATEC Biomedical (ETR:SBS) Investors: HSBC Keeps “Hold” Rating, Sees EUR 47.00/Share

November 28, 2016 - By Hazel Jackson

Rating Change: STRATEC Biomedical (ETR:SBS) Investors: HSBC Keeps

STRATEC Biomedical (ETR:SBS) Rating

In analysts report revealed to investors on Sunday morning, STRATEC Biomedical (ETR:SBS) stock had its “Hold” Rating restate by expert analysts at HSBC. They currently have a EUR 47.00 target price on company. HSBC’s target suggests a potential upside of 10.80% from the company’s last price.

Stratec Biomedical AG (ETR:SBS) Ratings Coverage

Out of 7 analysts covering STRATEC Biomedical (ETR:SBS), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. €65 is the highest target while €47 is the lowest. The €54.80 average target is 29.12% above today’s (€42.44) stock price. STRATEC Biomedical has been the topic of 21 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by HSBC on Wednesday, March 30. The stock of Stratec Biomedical AG (ETR:SBS) has “Sell” rating given on Friday, May 20 by DZ-Bank AG. The company was upgraded on Saturday, October 1 by Oddo & Cie. HSBC maintained Stratec Biomedical AG (ETR:SBS) rating on Sunday, November 27. HSBC has “Hold” rating and €47 price target. The rating was upgraded by Warburg Research on Friday, June 10 to “Buy”. Berenberg maintained Stratec Biomedical AG (ETR:SBS) on Saturday, February 13 with “Hold” rating. Berenberg maintained the stock with “Hold” rating in Friday, September 23 report. On Friday, September 2 the stock rating was upgraded by Warburg Research to “Buy”. As per Tuesday, April 12, the company rating was upgraded by Oddo & Cie. Berenberg maintained the stock with “Hold” rating in Wednesday, March 23 report.

About 708 shares traded hands. Stratec Biomedical AG (ETR:SBS) has risen 20.11% since April 25, 2016 and is uptrending. It has outperformed by 14.10% the S&P500.

Analysts await Companhia de Saneamento Basico (ADR) (NYSE:SBS) to report earnings on March, 24. They expect $0.21 EPS, up 23.53% or $0.04 from last year’s $0.17 per share. SBS’s profit will be $143.34 million for 10.24 P/E if the $0.21 EPS becomes a reality. After $0.26 actual EPS reported by Companhia de Saneamento Basico (ADR) for the previous quarter, Wall Street now forecasts -19.23% negative EPS growth.

STRATEC Biomedical AG is a Germany firm engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. The company has a market cap of 503.22 million EUR. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. It has a 36.08 P/E ratio. STRATEC’s partners market Company’s products to pharmaceutical laboratories, blood banks and research institutes throughout the world.

According to Zacks Investment Research, “SABESP provides public water and sewage services to residential, commercial, industrial and governmental customers in the City of Sao Paulo.”

SBS Company Profile

Companhia de Saneamento Basico do Estado de Sao Paulo-SABESP, incorporated on October 6, 1973, is a water and sewage service provider. The Firm provides water and sewage services to a range of residential, commercial, industrial and governmental clients in over 360 municipalities in the state of Sao Paulo, including the city of Sao Paulo. The Company’s divisions include Water and Sewage. The Firm also supplies treated water on a wholesale basis to approximately 10 municipalities located in the Sao Paulo metropolitan region and urban conurbations.

Another recent and important Stratec Biomedical AG (ETR:SBS) news was published by Nature.com which published an article titled: “Anaerobic oxidation of methane associated with sulfate reduction in a natural …” on December 04, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>